Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSGA6Z)

• Drug Name: Toripalimab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Demodex blepharitis	1G07	Approved in China	[1]
Melanoma	2C30	Approved in China	[1]
Urothelial carcinoma	2C92.0	Approved in China	[1]
Esophageal squamous cell carcinoma	2E60.1	Phase 3	[2]

• Cross-matching ID: TTD Drug ID: DMSGA6Z

Molecule-Related Drug Atlas

Drug(s) Targeting Programmed cell death protein 1 (PD-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nivolumab	DMAB9QE	Melanoma	2C30	Approved	[4]
Tislelizumab	DMGVUO5	Hodgkin lymphoma	2B30	Approved	[5]
MK-3475	DMBYNW0	Melanoma	2C30	Approved	[4]
Pembrolizumab	DMFQEA6	Melanoma	2C30	Approved	[6]
Cemiplimab	DMKMJHE	Cutaneous squamous cell carcinoma	2C30	Approved	[7]
Retifanlimab	DMRKTCP	Neuroendocrine cancer	2B72.1	Approved	[8]
Sintilimab	DMGWR0C	Hodgkin lymphoma	2B30	Approved	[9]
Dostarlimab	DM78NWP	Endometrial cancer	2C76	Approved	[10]
PDR001	DM53J6B	Melanoma	2C30	Phase 3	[11]
BGB-A317	DM7NJYC	Hepatocellular carcinoma	2C12.02	Phase 3	[8]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Programmed cell death protein 1 (PD-1)	TTNBFWK	PDCD1_HUMAN	Inhibitor	[3]

References

• [1] Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
• [2] ClinicalTrials.gov (NCT03829969) A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Compare Toripalimab Injection (JS001) Combined With Standard Chemotherapy Versus Placebo Combined With Standard Chemotherapy in Treatment of Advanced or Metastatic Esophageal Squamous Cell Cancer (ESCC) Without Previous Systemic Chemotherapy. U.S.National Institutes of Health.
• [3] Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
• [4] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [5] Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364.
• [6] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [7] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346.
• [10] Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)